Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 17/20 | 0.53 |
| ▸ | CDK8 | P49336 | 17/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3725771 | 0.90 | CCNC (0.53) | CCNCCDK8MKNK1MKNK2KDM4E | |
| SCHEMBL3721461 | 0.90 | RIPK1 (0.48) | MKNK1MKNK2KDM4EL3MBTL1RIPK1 | |
| SCHEMBL3663458 | 0.89 | TGFBR1 (0.52) | MKNK1MKNK2KDM4ERIPK1 | |
| SCHEMBL3722403 | 0.89 | CCNC (0.51) | CCNCCDK8MKNK1MKNK2KDM4E | |
| SCHEMBL3723739 | 0.88 | ABL1 (0.50) | CCNCCDK8KDM4EL3MBTL1RIPK1 | |
| SCHEMBL3719305 | 0.87 | CCNC (0.54) | CCNCCDK8MKNK1MKNK2KDM4E | |
| SCHEMBL3718037 | 0.87 | CCNC (0.51) | CCNCCDK8MKNK1MKNK2KDM4E | |
| SCHEMBL3723755 | 0.82 | L3MBTL1 (0.53) | KDM4EL3MBTL1RIPK1 | |
| SCHEMBL2238690 | 0.81 | HPGD (0.48) | CCNCCDK8KDM4EL3MBTL1RIPK1 | |
| SCHEMBL3725755 | 0.81 | ABL1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | CCNC 1584/4885CDK8 1506/4885MKNK1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.